Document:

EX-4.1

 Exhibit 4.1 
  

 
  

MARSH & McLENNAN COMPANIES, INC., 

Issuer, 
 and 

The Bank of New York Mellon, 

Trustee 
  

 
 FOURTH
SUPPLEMENTAL INDENTURE 
 Dated as of May 30, 2014 
  

 
 $600,000,000
aggregate principal amount of 3.500% Senior Notes due 2024 
  
  

 

 FOURTH SUPPLEMENTAL INDENTURE, dated as of May 30, 2014 between MARSH & McLENNAN
COMPANIES, INC., a Delaware corporation (the “Issuer”), and THE BANK OF NEW YORK MELLON, a New York banking corporation, as Trustee (the “Trustee”) 

W I T N E S S E T H: 
 WHEREAS,
the Issuer and the Trustee executed and delivered an Indenture, dated as of July 15, 2011 (the “Base Indenture” and, as supplemented hereby, the “Indenture”), to provide for the issuance by the Issuer from time
to time of senior debt securities evidencing its unsecured indebtedness, to be issued in one or more series as provided in the Indenture; 

WHEREAS, pursuant to a Board Resolution, the Issuer has authorized the issuance of a series of securities evidencing its senior indebtedness,
consisting initially of $600,000,000 aggregate principal amount of 3.500% Senior Notes due 2024 (the “Original Notes” and, together with all the Additional Notes (as defined herein), if any, hereinafter referred to, the
“Notes”); 
 WHEREAS, the entry into this Fourth Supplemental Indenture by the parties hereto is in all respects authorized
by the provisions of the Indenture; 
 WHEREAS, the Issuer desires to establish the terms of the Notes in accordance with Section 2.01
of the Indenture and to establish the form of the Notes in accordance with Section 2.02 of the Indenture; and 
 WHEREAS, all acts and
requirements necessary to make this Fourth Supplemental Indenture a valid and legally binding indenture and agreement according to its terms have been done. 

NOW, THEREFORE, for and in consideration of the premises, the Issuer and the Trustee mutually covenant and agree for the equal and
proportionate benefit of the respective holders from time to time of the Notes as follows: 
 ARTICLE 1 

Section 1.01. Terms of Notes. The following terms relating to the Notes are hereby established: 

(a) The Notes shall constitute a series of securities having the title “3.500% Senior Notes due 2024.” 

 (b) The aggregate principal amount of the Original Notes that may be authenticated and delivered
under the Indenture (except Notes authenticated and delivered upon registration of, transfer of, or in exchange for, or in lieu of, other Notes pursuant to Sections 2.05, 2.06, 2.07 or 9.04 of the Base Indenture) shall be up to $600,000,000. 

(c) The entire outstanding principal of the Notes shall be payable on June 3, 2024 plus any unpaid interest accrued to such date. 

(d) The rate at which the Notes shall bear interest shall be 3.500% per annum; the date from which interest shall accrue on the Notes shall be
May 30, 2014 or from the most recent Interest Payment Date to which interest has been paid; the Interest Payment Dates for the Notes on which interest will be payable shall be June 3 and December 3 in each year, beginning
December 3, 2014; the regular record dates for the interest payable on the Notes on any Interest Payment Date shall be the May 18 or November 18 immediately preceding the applicable Interest Payment Date; and the basis upon which
interest on the Notes shall be calculated shall be that of a 360-day year consisting of twelve 30-day months. 

(e) (i) The Notes may be redeemed in whole at any time or in part from time to time, at the option of the Issuer. 

(ii) The redemption price (the “Redemption Price”) of the Notes to be redeemed shall be calculated as follows,
plus, in each case, accrued and unpaid interest on the principal amount being redeemed to but excluding the redemption date: 

(A) If the redemption date is prior to March 3, 2024, the Notes may be redeemed by the Issuer at a Redemption Price equal
to the greater of (1) 100% of the principal amount of the Notes to be redeemed and (2) the sum of the present values of the remaining scheduled payments of principal of and interest on the Notes to be redeemed (exclusive of interest
accrued to the date of redemption) discounted to the date of redemption on a semi-annual basis (assuming a 360-day year consisting of twelve 30-day months) at the then current Treasury Rate plus 15 basis points. 

(B) If the redemption date is on or after March 3, 2024, the Notes may be redeemed by the Issuer at a Redemption Price
equal to 100% of the principal amount of the Notes to be redeemed. 
 (iii) (A) In case the Issuer shall desire to
exercise such right to redeem all or, as the case may be, a portion of the Notes in accordance with Section 1.01(e)(i) above, the Issuer shall, or shall cause the Trustee to, give notice of such redemption to holders of the Notes to

  
 2 

 
be redeemed by transmitting a notice of such redemption not less than 30 days and not more than 60 days before the date fixed for redemption to such holders as they shall appear upon the Security
Register; provided, however, if the Trustee is asked to give the notice, the Issuer will give the Trustee at least 3 days advance notice of the date of publication of such notice. Any notice that is mailed in the manner herein provided shall be
conclusively presumed to have been duly given, whether or not the registered holder received the notice. In any case, failure duly to give such notice to the holder of any Note designated for redemption in whole or in part, or any defect in the
notice, shall not affect the validity of the proceedings for the redemption of any other Note. 
 Each such notice of
redemption shall specify the amount of Notes to be redeemed, the date fixed for redemption and the applicable Redemption Price at which the Notes are to be redeemed, and shall state that payment of the Redemption Price of such Notes to be redeemed
will be made at the office or agency of the Issuer in the Borough of Manhattan, the City and State of New York, upon presentation and surrender of such Notes, that interest accrued to the date fixed for redemption will be paid as specified in said
notice and, that from and after said date interest will cease to accrue; except that interest shall continue to accrue on any such Note or portion thereof with respect to which the Issuer defaults in the payment of such Redemption Price and accrued
interest. If less than all the Notes are to be redeemed, the notice to the holders of the Notes to be redeemed in whole or in part shall specify the particular Notes to be redeemed. In case the Notes are to be redeemed in part only, the notice shall
state the portion of the principal amount thereof to be redeemed, and shall state that on and after the redemption date, upon surrender of such security, a new Note in principal amount equal to the unredeemed portion thereof will be issued. 

(B) If less than all the Notes are to be redeemed, the Issuer shall give the Trustee at least 45 days’ notice in advance
of the date fixed for redemption as to the aggregate principal amount of Notes to be redeemed, and thereupon the Trustee shall select, by lot or in such other manner in accordance with the procedures of the Depository or as the Trustee shall deem
appropriate and fair in its discretion and that may provide for the selection of a portion or portions (equal to two thousand U.S. dollars ($2,000) or integral multiples of $1,000 in excess thereof) of the principal amount of such Notes of a
denomination larger than $2,000, the Notes to be redeemed and shall thereafter promptly notify the Issuer in writing of the numbers of the Notes to be redeemed, in whole or in part. 

  
 3 

 The Issuer may, if and whenever it shall so elect, by delivery of instructions
signed on its behalf by its President or any Vice President, instruct the Trustee or any paying agent to call all or any part of the Notes for redemption and to give notice of redemption in the manner set forth in this Section, such notice to be in
the name of the Issuer or its own name as the Trustee or such paying agent may deem advisable. In any case in which notice of redemption is to be given by the Trustee or any such paying agent, the Issuer shall deliver or cause to be delivered to, or
permit to remain with, the Trustee or such paying agent, as the case may be, such Security Register, transfer books or other records, or suitable copies or extracts therefrom, sufficient to enable the Trustee or such paying agent to give any notice
that may be required under the provisions of this Section. 
 Subject to Section 2.11 of the Base Indenture, the Issuer
shall not be required (i) to issue, register the transfer of or exchange any Notes during a period beginning at the opening of business 15 days before the day of the delivery of a notice of redemption of the Notes selected for redemption and
ending at the close of business on the day of such mailing, or (ii) to register the transfer of or exchange any Notes so selected for redemption in whole or in part, except the unredeemed portion of any such Notes being redeemed in part. 

If the giving of notice of redemption shall have been completed as above provided, the Notes or portions of the Notes to be
redeemed specified in such notice shall become due and payable on the date and at the place stated in such notice at the applicable Redemption Price, and interest on such Notes shall cease to accrue on and after the date fixed for redemption, unless
the Issuer shall default in the payment of such Redemption Price and accrued interest. 
 (iv) As used herein: 

“Business Day” means any day that is not a Saturday, Sunday or other day on which commercial banks in New York, New
York are authorized or required by law to remain closed.  
 “Comparable Treasury Issue” means the United
States Treasury security selected by the Independent Investment Banker as having an actual or interpolated maturity comparable to the remaining term of the Notes to be redeemed that would be utilized, at the time of selection and in accordance with
customary financial practice, in pricing new issues of corporate debt securities of comparable maturity to the remaining term of such Notes. 

  
 4 

 “Comparable Treasury Price” means, with respect to any redemption date,
(1) the average of the Reference Treasury Dealer Quotations for such redemption date, after excluding the highest and lowest Reference Treasury Dealer Quotations, or (2) if the Independent Investment Banker is provided with fewer than four
such Reference Treasury Dealer Quotations, the average of all such quotations. 
 “Independent Investment
Banker” means one of the Reference Treasury Dealers appointed by the Issuer. 
 “Reference Treasury Dealer”
means (i) J.P.Morgan Securities LLC and its successors, (ii) Morgan Stanley & Co. LLC and its successors, (iii) Barclays Capital Inc. and its successors and (iv) Citigroup Global Markets Inc. and its successors, or one
or more Reference Treasury Dealers as the Issuer may specify from time to time; provided, however, that if any of them ceases to be a primary U.S. Government securities dealer for The City of New York (each a “Primary Treasury
Dealer”), the Issuer will substitute another Primary Treasury Dealer. 
 “Reference Treasury Dealer Quotations”
means, with respect to each Reference Treasury Dealer and any redemption date, the average, as determined by the Independent Investment Banker, of the bid and asked prices for the Comparable Treasury Issue (expressed as a percentage of its principal
amount) quoted in writing to the Independent Investment Banker by such Reference Treasury Dealer at 5:00 p.m., New York City time, on the third Business Day preceding such redemption date. 

“Treasury Rate” means, with respect to any redemption date, the rate per year equal to the semiannual equivalent yield
to maturity or interpolated (on a day count basis) of the Comparable Treasury Issue, calculated using a price for the Comparable Treasury Issue (expressed as a percentage of its principal amount) equal to the Comparable Treasury Price for such
redemption date. 
 The Treasury Rate shall be calculated on the third Business Day preceding the redemption date. 

With respect to Section 1.01(e)(i)(A) above, the Trustee shall be entitled to conclusively rely upon the calculations of the Independent
Investment Banker. 
 (f) The Notes shall be issuable in denominations equal to two thousand U.S. dollars ($2,000) or integral multiples of
$1,000 in excess thereof. 
 (g) The Trustee shall also be the security registrar and paying agent for the Notes. 

  
 5 

 (h) Payments of the principal of and interest on the Notes shall be made in U.S. dollars, and the
Notes shall be denominated in U.S. dollars. 
 (i) The holders of the Notes shall have no special rights in addition to those provided in
the Indenture upon the occurrence of any particular events. 
 (j) The Notes shall not be subordinated to any other debt of the Issuer, and
shall constitute senior unsecured obligations of the Issuer. 
 (k) The Notes shall be issued as a Global Security and The Depository Trust
Company, New York, New York shall be the initial Depository. The Notes are not convertible into shares of common stock or other securities of the Issuer. 

Section 1.02. Form of Note. The form of the Notes is attached hereto as Exhibit A. 

Section 1.03. Additional Notes. Subject to the terms and conditions contained herein, the Issuer may issue additional notes (the
“Additional Notes”) having the same ranking and the same interest rate, maturity and other terms as the Original Notes (except as otherwise described in the form of the Notes), without the consent of the holders of the Original
Notes then Outstanding. Any such Additional Notes will be a part of the series having the same terms as the Original Notes. The aggregate principal amount of the Additional Notes, if any, shall be unlimited. The Original Notes and the Additional
Notes, if any, of such series shall constitute one series for all purposes under this Fourth Supplemental Indenture, including, without limitation, amendments, waivers and redemptions. 

Section 1.04 Amendment of Section 6.01(a)(i) of the Base Indenture. Solely for the purposes of the Notes,
Section 6.01(a)(i) of the Base Indenture is hereby amended by replacing that section in its entirety with the following: 

“the Company defaults in the payment of any installment of interest on the Notes (as defined in this Supplemental Indenture), as and when
the same shall become due and payable, and continuance of such default for a period of 30 days; provided, however, that a valid extension of an interest payment period by the Company in accordance with the terms of any indenture supplemental hereto,
shall not constitute a default in the payment of interest for this purpose.” 

  
 6 

 ARTICLE 2 

MISCELLANEOUS 

Section 2.01. Definitions. Capitalized terms used but not defined in this Fourth Supplemental Indenture shall have the meanings
ascribed thereto in the Indenture. 
 Section 2.02. Confirmation of Indenture. The Indenture, as heretofore supplemented and
amended and as further supplemented and amended by this Fourth Supplemental Indenture, is in all respects ratified and confirmed, and the Indenture, this Fourth Supplemental Indenture and all indentures supplemental thereto shall be read, taken and
construed as one and the same instrument. 
 Section 2.03. Concerning the Trustee. The Trustee assumes no duties,
responsibilities or liabilities by reason of this Fourth Supplemental Indenture other than as set forth in the Indenture and, in carrying out its responsibilities hereunder, shall have all of the rights, protections and immunities which it possesses
under the Indenture. The Trustee makes no representations as to the validity or sufficiency of this Fourth Supplemental Indenture. The recitals herein are deemed to be those of the Issuer and not of the Trustee. 

Section 2.04. Governing Law. This Fourth Supplemental Indenture, the Indenture and the Notes shall be governed by and construed in
accordance with the law of the State of New York. 
 Section 2.05. Separability. In case any provision in this Fourth
Supplemental Indenture shall for any reason be held to be invalid, illegal or unenforceable, the validity, legality and enforceability of the remaining provisions shall not in any way be affected or impaired thereby. 

Section 2.06. Counterparts. This Fourth Supplemental Indenture may be executed in any number of counterparts each of which shall
be an original, but such counterparts shall together constitute but one and the same instrument. 

  
 7 

 IN WITNESS WHEREOF, this Fourth Supplemental Indenture has been duly executed by the Issuer and
the Trustee as of the day and year first written above. 
  

			
	MARSH & McLENNAN COMPANIES, INC.
		
	By:	 	  

		 	Name:
		 	Title:

  

			
	Attest:
		
	    By:	 	  

		 	Name:
		 	Title:

 
			
	THE BANK OF NEW YORK MELLON,
    as Trustee
		
	By:	 	  

		 	Name:
		 	Title:

 Exhibit A 

UNLESS THIS CERTIFICATE IS PRESENTED BY AN AUTHORIZED REPRESENTATIVE OF THE DEPOSITARY TRUST COMPANY, A NEW YORK CORPORATION (“DTC”), TO
THE ISSUER OR ITS AGENT FOR REGISTRATION OF TRANSFER, EXCHANGE, OR PAYMENT, AND ANY CERTIFICATE ISSUED IS REGISTERED IN THE NAME OF CEDE & CO. OR IN SUCH OTHER NAME AS IS REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF DTC (AND ANY PAYMENT IS
MADE TO CEDE & CO. OR TO SUCH OTHER ENTITY AS IS REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF DTC), ANY TRANSFER, PLEDGE, OR OTHER USE HEREOF FOR VALUE OR OTHERWISE BY OR TO ANY PERSON IS WRONGFUL INASMUCH AS THE REGISTERED OWNER HEREOF,
CEDE & CO, HAS AN INTEREST HEREIN. 
 UNLESS AND UNTIL IT IS EXCHANGED IN WHOLE OR IN PART FOR SECURITIES IN DEFINITIVE FORM IN ACCORDANCE WITH THE
PROVISIONS OF THE INDENTURE AND THE TERMS OF THE SECURITIES AND EXCEPT AS OTHERWISE PROVIDED IN SECTION 2.11 OF THE BASE INDENTURE, THIS NOTE MAY NOT BE TRANSFERRED EXCEPT AS A WHOLE BY DTC TO A NOMINEE OF DTC OR BY A NOMINEE OF DTC TO DTC OR
ANOTHER NOMINEE OF DTC OR BY DTC OR ANY SUCH NOMINEE TO A SUCCESSOR DEPOSITARY OR A NOMINEE OF SUCH SUCCESSOR DEPOSITARY. 

  
 A-1 

			
	 Certificate No. [1/2]

CUSIP No. 571748AV4
 ISIN No. US571748AV42
	 	$[500,000,000/$100,000,000]

 MARSH & McLENNAN COMPANIES, INC. 

3.500% Senior Notes due 2024 

MARSH & McLENNAN COMPANIES, INC., a Delaware corporation (the “Issuer”, which term includes any successor
corporation under the Indenture hereinafter referred to), for value received, hereby promises to pay to CEDE & Co., or its registered assigns, the principal sum of [FIVE HUNDRED MILLION DOLLARS/ONE HUNDRED MILLION DOLLARS]
($[500,000,000/$100,000,000]) (which aggregate principal amount may from time to time be increased or decreased to such other aggregate principal amounts by adjustments made on the Schedule of Increases or Decreases in Global Security attached
hereto) on June 3, 2024 and to pay interest on said principal sum from May 30, 2014 or from the most recent interest payment date (each such date, an “Interest Payment Date”) to which interest has been paid or duly
provided for semiannually on June 3 and December 3 of each year commencing December 3, 2014 at the rate of 3.500% per annum until the principal hereof shall have become due and payable, and on any overdue principal and premium,
if any, and (without duplication and to the extent that payment of such interest is enforceable under applicable law) on any overdue installment of interest at the same rate per annum. The amount of interest payable on any Interest Payment Date
shall be computed on the basis of a 360-day year of twelve 30-day months. In the event that any date on which interest is payable on this Note is not a Business Day,
then payment of interest payable on such date will be made on the next succeeding day which is a Business Day (and without any interest or other payment in respect of any such delay). The interest installment so payable, and punctually paid or duly
provided for, on any Interest Payment Date will, as provided in the Indenture (hereafter defined), be paid to the person in whose name this Note (or one or more Predecessor Securities, as defined in said Indenture) is registered at the close of
business on the regular record date for such interest installment which shall be the May 18 or November 18 preceding such Interest Payment Date. Any such interest installment not punctually paid or duly provided for (as defined in the
Indenture, the “Defaulted Interest”) shall forthwith cease to be payable to the registered holders on such regular record date, and may be paid to the person in whose name this Note (or one or more Predecessor Securities) is
registered at the close of business on a special record date to be fixed by the Trustee for the payment of such Defaulted Interest, which shall not be more than 15 nor less than 10 days prior to the date of the proposed payment, and not less than 10
days after the receipt by the Trustee of the notice of the proposed payment 

  
 A-2 

 
or at any time in any other lawful manner not inconsistent with the requirements of any securities exchange on which the Notes may be listed, and upon such notice as may be required by such
exchange, all as more fully provided in the Indenture. The principal of (and premium, if any) and the interest on this Note shall be payable at the office or agency of the Trustee maintained for that purpose in any coin or currency of the United
States of America which at the time of payment is legal tender for payment of public and private debts; provided, however, that payment of interest may be made at the option of the Issuer by check mailed to the registered holder at
such address as shall appear in the Security Register. Notwithstanding the foregoing, so long as the registered holder of this Note is Cede & Co., the payment of the principal of (and premium, if any) and interest on this Note will be made
at such place and to such account as may be designated by DTC. 
 The indebtedness evidenced by this Note is, to the extent provided in the
Indenture, senior and unsecured and will rank in right of payment on parity with all other senior unsecured obligations of the Issuer. 

This Note shall not be entitled to any benefit under the Indenture hereinafter referred to or be valid until the Certificate of Authentication
hereon shall have been signed manually by or on behalf of the Trustee. 
 The provisions of this Note are continued on the reverse side
hereof and such continued provisions shall for all purposes have the same effect as though fully set forth at this place. 

  
 A-3 

 IN WITNESS WHEREOF, the Issuer has caused this instrument to be executed. 

Dated: 
  

			
	MARSH & McLENNAN COMPANIES, INC.
		
	By:	 	  

		 	Name:
		 	Title:

 
			
		
	By:	 	  

		 	Name:
		 	Title:

  

			
	Attest:
		
	    By:	 	  

		 	Name:
		 	Title:

  
 A-4 

 CERTIFICATE OF AUTHENTICATION 

This is one of the Notes of the series of Notes described in the within-mentioned Indenture. 

THE BANK OF NEW YORK MELLON, as Trustee 

			
		
	By	 	 
		 	Authorized Signatory

Dated:                         
                                         
             

  
 A-5 

 ASSIGNMENT FORM 

FOR VALUE RECEIVED, the undersigned hereby 

sells, assigns and transfers to 
  

	
	 
	(Insert Social Security number or other identifying number of assignee)

  

	
	 
	(Please print or typewrite name and address, including zip code of assignee)

  

	
	 

 the within Note of Marsh & McLennan Companies, Inc. and hereby does irrevocably constitute and appoint 

 
  

Attorney to transfer said Note on the books of the within-named Issuer with full power of substitution in the premises.

  

							
	Dated:	  	 	  		  	 

  
  

Signature(s) must be guaranteed by an eligible Guarantor Institution (banks, stock brokers, savings and loan associations and credit unions) with membership
in an approved signature guarantee medallion program pursuant to Securities and Exchange Commission Rule 17Ad-15. 

NOTICE: The signature to this assignment must correspond with the name as it appears on the first page of the within Note in every particular, without
alteration or enlargement or any change whatever. 

  
 A-6 

 SCHEDULE OF INCREASES OR DECREASES IN GLOBAL SECURITY 

MARSH & McLENNAN COMPANIES, INC. 

3.500% Senior Notes due 2024 
 The
initial aggregate principal amount of this Global Security is $[500,000,000/$100,000,000]. The following increases or decreases in this Global Security have been made: 

No:              
  

							
	 Date
	 	 Principal Amount of this
Global Security
	 	 Notation Explaining
Principal Amount Recorded
	 	 Signature of authorized
officer of Trustee
or
Depositary

				
	  
	 	  
	 	  
	 	  

				
	  
	 	  
	 	  
	 	  

				
	  
	 	  
	 	  
	 	  

				
	  
	 	  
	 	  
	 	  

  
 A-7 

 MARSH & McLENNAN COMPANIES, INC. 

3.500% Senior Notes due 2024 

This Note is one of a duly authorized series of Securities (referred to in the Base Indenture (hereafter defined)), of the Issuer (herein
sometimes referred to as the “Notes”), all such Securities issued or to be issued in one or more series under and pursuant to an indenture (the “Base Indenture”), dated as of July 15, 2011 between the Issuer
and The Bank of New York Mellon, as Trustee (the “Trustee”), as supplemented in the case of the Notes by the Fourth Supplemental Indenture, dated as of May 30, 2014, between the Issuer and the Trustee (the Base Indenture, as so
supplemented, the “Indenture”), to which Indenture and all indentures supplemental thereto reference is hereby made for a description of the rights, limitations of rights, obligations, duties and immunities thereunder of the
Trustee, the Issuer and the holders of the Notes. This series of Notes is initially limited in aggregate principal amount as specified in said Fourth Supplemental Indenture. This series of Notes and any Additional Notes of this series shall
constitute one series for all purposes under the Indenture, including without limitation, amendments, waivers and redemptions. The terms and conditions of this series of Notes and any Additional Notes of this series (other than the issue price, the
date of issuance, the payment of interest accruing prior to the issue date of the Additional Notes and the first payment of interest following such issue date) shall be the same and shall bear the same CUSIP number. 

The Notes may be redeemed in whole at any time or in part from time to time, at the option of the Issuer. The redemption price (the
“Redemption Price”) of the Notes to be redeemed shall be calculated as follows, plus, in each case, accrued and unpaid interest on the principal amount being redeemed to but excluding the redemption date: 

(a) If the redemption date is prior to March 3, 2024, the Notes may be redeemed by the Issuer at a Redemption Price equal to the greater
of (1) 100% of the principal amount of the Notes and (2) the sum of the present values of the remaining scheduled payments of principal of and interest on the Notes (exclusive of interest accrued to the date of redemption) discounted to
the date of redemption on a semi-annual basis (assuming a 360-day year consisting of twelve 30-day months) at then current Treasury Rate plus 15 basis points. 

(b) If the redemption date is on or after March 3, 2024, the Notes may be redeemed by the Issuer at a Redemption Price equal to 100% of
the principal amount of the Notes. 
 In case the Issuer shall desire to exercise such right to redeem all or, as the case may be, a portion
of the Notes, the Issuer shall, or shall cause the Trustee to, give notice of such redemption to holders of the Notes to be redeemed by transmitting a notice of such redemption not less than 30 days and not more than

  
 A-8 

 
60 days before the date fixed for redemption to such holders as they shall appear upon the Security Register; provided, however, if the Trustee is asked to give the notice, the Issuer will give
the Trustee at least 3 days advance notice of the date of publication of such notice. Any notice that is mailed in the manner herein provided shall be conclusively presumed to have been duly given, whether or not the registered holder received the
notice. In any case, failure duly to give such notice to the holder of any Note designated for redemption in whole or in part, or any defect in the notice, shall not affect the validity of the proceedings for the redemption of any other Note. 

Each such notice of redemption shall specify the amount of Notes to be redeemed, the date fixed for redemption and the applicable Redemption
Price at which the Notes are to be redeemed, and shall state that payment of the Redemption Price of such Notes to be redeemed will be made at the office or agency of the Issuer in the Borough of Manhattan, the City and State of New York, upon
presentation and surrender of such Notes, that interest accrued to the date fixed for redemption will be paid as specified in said notice and, that from and after said date interest will cease to accrue; except that interest shall continue to accrue
on any such Note or portion thereof with respect to which the Issuer defaults in the payment of such Redemption Price and accrued interest. If less than all the Notes are to be redeemed, the notice to the holders of the Notes to be redeemed in whole
or in part shall specify the particular Notes to be redeemed. In case any Note is to be redeemed in part only, the notice that relates to such Note shall state the portion of the principal amount thereof to be redeemed, and shall state that on and
after the redemption date, upon surrender of such security, a new Note in principal amount equal to the unredeemed portion thereof will be issued. 

If less than all the Notes are to be redeemed, the Issuer shall give the Trustee at least 45 days’ notice in advance of the date fixed
for redemption as to the aggregate principal amount of Notes to be redeemed, and thereupon the Trustee shall select, by lot or in such other manner in accordance with the procedures of the Depository or as the Trustee shall deem appropriate and fair
in its discretion and that may provide for the selection of a portion or portions (equal to two thousand U.S. dollars ($2,000) or integral multiples of $1,000 in excess thereof) of the principal amount of such Notes of a denomination larger than
$2,000, the Notes to be redeemed and shall thereafter promptly notify the Issuer in writing of the numbers of the Notes to be redeemed, in whole or in part. 

The Issuer may, if and whenever it shall so elect, by delivery of instructions signed on its behalf by its President or any Vice President,
instruct the Trustee or any paying agent to call all or any part of the Notes for redemption and to give notice of redemption in the manner set forth in this Note, such notice to be in the name of the Issuer or its own name as the Trustee or such
paying agent may deem advisable. In any case in which notice of redemption is to be given by the Trustee or any such paying agent, the Issuer shall deliver or cause to be delivered 

  
 A-9 

 
to, or permit to remain with, the Trustee or such paying agent, as the case may be, such Security Register, transfer books or other records, or suitable copies or extracts therefrom, sufficient
to enable the Trustee or such paying agent to give any notice by mail that may be required under the provisions stated herein. 
 Subject to
Section 2.11 of the Base Indenture, the Issuer shall not be required (i) to issue, register the transfer of or exchange any Notes during a period beginning at the opening of business 15 days before the day of the delivery of a notice of
redemption of the Notes selected for redemption and ending at the close of business on the day of such mailing, or (ii) to register the transfer of or exchange any Notes so selected for redemption in whole or in part, except the unredeemed
portion of any such Notes being redeemed in part. 
 If the giving of notice of redemption shall have been completed as above provided, the
Notes or portions of the Notes to be redeemed specified in such notice shall become due and payable on the date and at the place stated in such notice at the applicable Redemption Price, and interest on such Notes shall cease to accrue on and after
the date fixed for redemption, unless the Issuer shall default in the payment of such Redemption Price and accrued interest. 
 The
Indenture contains provisions permitting the Issuer and the Trustee, with the consent of the holders of not less than a majority in aggregate principal amount of the Securities of all of the series at the time Outstanding affected thereby (all such
series voting together as a single class), as defined in the Indenture, to execute supplemental indentures for the purpose of adding any provisions to or changing in any manner or eliminating any of the provisions of the Base Indenture or of any
supplemental indenture or of modifying in any manner the rights of the holders of the Notes; provided, however, that no such supplemental indenture shall, without the consent of the holders of each Security then Outstanding and affected
thereby (i) extend the fixed maturity of any Securities, including the Notes, or reduce the principal amount thereof, or reduce the rate or extend the time of payment of interest thereon, or reduce any premium payable upon the redemption
thereof, or (ii) reduce the aforesaid percentage of Securities, the holders of which are required to consent to any such supplemental indenture. The Indenture also contains provisions permitting the holders of a majority in aggregate principal
amount of the Securities of all series at the time Outstanding affected thereby (all such series voting together as a single class), to waive any past default in the performance of any of the covenants contained in the Base Indenture, or established
pursuant to the Base Indenture with respect to such series, and its consequences, except a default in the payment of the principal of or premium, if any, or interest on any Securities, including the Notes, in which case, each such affected series
voting as a separate class. Any such consent or waiver by the registered holder of this Note (unless revoked as provided in the Base Indenture) shall be conclusive and binding upon such holder and upon all future holders and owners of this Note and
of any Note issued in exchange herefor or in place hereof (whether by registration of transfer or otherwise), irrespective of whether or not any notation of such consent or waiver is made upon this Note. 

  
 A-10 

 No reference herein to the Indenture and no provision of this Note or of the Indenture shall
alter or impair the obligation of the Issuer, which is absolute and unconditional, to pay the principal of and premium, if any, and interest on this Note at the time and place and at the rate and in the money herein prescribed. 

The Issuer is subject to certain covenants contained in the Indenture with respect to, and for the benefit of the holders of, the Notes. The
Trustee shall not be obligated to monitor or confirm, on a continuing basis or otherwise, the Issuer’s compliance with the covenants contained in the Indenture or with respect to reports or other certificates filed under the Indenture;
provided, however, that nothing herein shall relieve the Trustee of any obligations to monitor the Issuer’s timely delivery of all reports and certificates required under Section 5.03 of the Base Indenture and to fulfill its
obligations under Article VII of the Indenture. If an Event of Default as defined in the Indenture with respect to the Notes shall occur and be continuing, the principal of the Notes may be declared due and payable in the manner and with the
effect provided in the Indenture. 
 As provided in and subject to the provisions of the Indenture, the holder of this Note shall not have
the right to institute any proceeding with respect to the Indenture or for the appointment of a receiver or Trustee or for any other remedy thereunder, unless such holder shall have previously given the Trustee written notice of a continuing Event
of Default with respect to the Notes, the holders of not less than 25% in principal amount of the Outstanding Notes (in the case of an Event of Default described in clauses (a)(i) or (a)(ii) of Section 6.01 of the Base Indenture, each such
series voting as a separate class, and in the case of an Event of Default described in clauses (a)(iii), (a)(iv), (a)(v) or (a)(vi) of Section 6.01 of the Base Indenture, all affected series voting together as a single class) shall have made
written request to the Trustee to institute proceedings in respect of such Event of Default as Trustee and offered the Trustee reasonable indemnity and the Trustee shall have failed to institute any such proceeding for 60 days after receipt of
such notice, request and offer of indemnity and the Trustee shall not have received from the holders of a majority in principal amount of the Notes at the time Outstanding (voting as provided in Section 6.04(b) of the Base Indenture) a
direction inconsistent with such request. The foregoing shall not apply to any suit instituted by the holder of this Note for the enforcement of any payment of principal hereof or any interest on or after the respective due dates expressed herein.

 As provided in the Indenture and subject to certain limitations therein set forth, this Note is transferable by the registered holder
hereof on the Security Register of the Issuer, upon surrender of this Note for registration of transfer at the office or agency of the Issuer in the Borough of Manhattan, the City and State 

  
 A-11 

 
of New York accompanied by a written instrument or instruments of transfer in form satisfactory to the Issuer or the Trustee duly executed by the registered holder hereof or his attorney
duly authorized in writing, and thereupon one or more new Notes of authorized denominations and for the same aggregate principal amount and series will be issued to the designated transferee or transferees. No service charge will be made for any
such transfer, but the Issuer may require payment of a sum sufficient to cover any tax or other governmental charge payable in relation thereto. 

Prior to due presentment for registration of transfer of this Note, the Issuer, the Trustee, any paying agent and any Security Registrar may
deem and treat the registered holder hereof as the absolute owner hereof (whether or not this Note shall be overdue and notwithstanding any notice of ownership or writing hereon made by anyone other than the Security Registrar) for the purpose of
receiving payment of or on account of the principal hereof and premium, if any, and interest due hereon and for all other purposes, and neither the Issuer nor the Trustee nor any paying agent nor any Note Registrar shall be affected by any notice to
the contrary. 
 No recourse shall be had for the payment of the principal of or the interest on this Note, or for any claim based hereon,
or otherwise in respect hereof, or based on or in respect of the Indenture, against any incorporator, stockholder, officer or director, past, present or future, as such, of the Issuer or of any predecessor or successor corporation, whether by virtue
of any constitution, statute or rule of law, or by the enforcement of any assessment or penalty or otherwise, all such liability being, by the acceptance hereof and as part of the consideration for the issuance hereof, expressly waived and released.

 The Notes are issuable only in registered form without coupons in authorized denominations. As provided in the Indenture and subject to
certain limitations herein and therein set forth, Notes so issued are exchangeable for a like aggregate principal amount of Notes of a different authorized denomination, as requested by the holder surrendering the same. 

All terms used in this Note which are defined in the Indenture shall have the meanings assigned to them in the Indenture. 

THE INDENTURE AND THE NOTES INCLUDING THIS NOTE SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE LAW OF THE STATE OF NEW YORK.

 Pursuant to a recommendation promulgated by the Committee on Uniform Security Identification Procedures, the Issuer has caused
“CUSIP” numbers to be printed on the Notes as a convenience to the holders of the Notes. No representation is made as to the correctness or accuracy of such CUSIP numbers as printed on the Notes, and reliance may be placed only on the
other identification numbers printed hereon. 

  
 A-12 

 Unless the certificate of authentication hereon has been executed by or on behalf of the Trustee
by manual signature, this Note shall not be entitled to any benefit under the Indenture or be valid or obligatory for any purposes. 

  
 A-13EX-10.1

 Exhibit 10.1 

FIRST PHYSICIANS CAPITAL GROUP, INC. 

EMPLOYMENT AGREEMENT 
 THIS
EMPLOYMENT AGREEMENT is made and entered into this 1st day of July, 2014, by and between First Physicians Capital Group, Inc., a Delaware corporation (“the Company”), and Sean Kirrane, an individual (“the Employee”). 

RECITALS 
 WHEREAS, the
Employee desires to be employed and continue to be employed by the Company in a position of trust and confidence in which Employee will learn, develop, create and have access to, and the Company shall disclose to Employee, confidential and
proprietary information. Aside from expectations regarding Employee’s employment performance, the Company also has requirements concerning Employee’s conduct, as an employee and following the cessation of employment, with respect to
information and contacts which Employee would not have acquired or made except through employment by the Company. The Company desires to be assured of the association and services of the Employee and to enter into this agreement pertaining to the
Employee’s duties with respect to non-competition, confidential information, and the duty of non-solicitation following Employee’s termination or separation from the Company (“Agreement”); and 

WHEREAS, the Employee is willing and desires to be employed and continue to be employed by the Company and enter into such Agreement. 

NOW, THEREFORE, in consideration of the mutual terms, covenants and conditions hereinafter set forth, the parties hereto do hereby agree as
follows: 
 ARTICLE I 

EMPLOYMENT 
 1.1
Agreement to Employ. Upon the terms and subject to the conditions of this Agreement, the Company hereby agrees to employ the Employee as President & Chief Executive Officer subject to the supervision and direction of the
Company’s Board of Directors (“Board”). 
 1.2 Term of Employment. The term of this Agreement will be for a period of
one (1) year commencing on the date hereof unless terminated earlier pursuant to Article VI below (“Employment Period”), provided however, that the Employee’s obligations in Article V and Article VII below will continue in effect
after such termination. 
 1.3 Renewal. Terms of any renewal of this Agreement or of any new agreement related to Employee’s
employment shall be completed or the decision made not to negotiate a renewal or new agreement made, not later than the end of the tenth (10th) month of the term of the Agreement. This Agreement and all its terms and conditions shall continue
in effect until terminated. 

 ARTICLE II 

COMPENSATION 
 2.1 Base
Salary. For all services rendered by the Employee under this Agreement, the Company will pay the Employee a base salary of Three Hundred and Sixty Thousand dollars ($360,000) per year (“Base Salary”). The Company will pay the Employee
the Base Salary not less frequently than in equal bimonthly installments in accordance with the Company’s payroll schedule. The Base Salary is subject to change in the sole discretion of the Company, provided that in no event shall
Employee’s annual compensation be reduced while this Agreement shall be in force. 
 2.2 Additional Compensation. The Company, in
its sole discretion, may reward Employee with a performance based bonus of up to 100% of the Employee’s annual salary, or such additional amounts as may determined by the Board, commensurate with his achievement of the strategic goals and
objectives of this position and any other factors the Board deems appropriate in its sole discretion. Within 90 days of the commencement of this Agreement, the Company and Employee shall identify strategic objective and goals for the contract year
that are acceptable to both parties. This additional compensation may be available to Employee, at the Company’s sole discretion, upon completion of this Agreement. 

2.3 Equity Incentives. The Employee will be eligible to participate in a management equity compensation plan, should one be created
during the term of Employee’s contract. Participation in any such plan shall be determined in the sole discretion of the Board. 

ARTICLE III 
 BENEFITS,
PERQUISITES AND EXPENSES 
 3.1 Benefits. During the Employment Period, the Employee will be eligible to participate in
(a) any welfare benefit plan sponsored or maintained by the Company, including, without limitation, each group life, hospitalization, medical, dental, health, accident or disability insurance or similar plan or program of the Company, and
(b) any pension, retirement, deferred compensation or savings plan sponsored or maintained by the Company, in each case, whether now existing or established hereafter, to the extent that the Employee is eligible to participate in any such plan
under the generally applicable provisions thereof. Nothing in this Paragraph 3.1 will limit the Company’s right to amend or terminate any such plan in accordance with the procedures set forth therein.  

3.2 Vacation. During the Employment Period, the Employee will be entitled to accrue four (4) weeks personal time off annually as is
generally provided to other employees of the Company in accordance with the then current policies and practices of the Company. 

  
 2 

 ARTICLE IV 

SCOPE OF DUTIES 
 4.1
Role of Employee. The Company employs, engages and hires Employee to serve as a member of the executive leadership team to participate in key decisions pertaining to the strategic initiatives, operating model and operation execution. Employee
shall perform such other duties as are customarily performed by one holding such position in other, same or similar businesses or enterprises as that engaged in by the Company, and shall also additionally render such other related services and
duties as may be assigned to him 
 4.2 General Specification of Duties. The Employee, during the term hereof, will be responsible for
performing all services, acts, or things necessary or advisable to manage and conduct the business of the Company consistent with his or her position as outlined in the job description provided to Employee, and further subject to such policies and
procedures as may be established by the officers and the Board. 
 4.3 Best Efforts. Employee agrees that he will at all times
faithfully, industriously, and to the best of his ability, experience, and talents, perform all of the duties that may be required of and from him pursuant to the express and implicit terms of this Agreement, to the reasonable satisfaction of the
Company. Employee will begin employment on a mutually agreed date. 
 ARTICLE V 

NONSOLICITATION, CONFIDENTIALITY AND NONCOMPETITION 

5.1 The Employee’s Devotion of Time. The Employee hereby agrees to devote his or her full time, abilities and energy to the
faithful performance of the duties assigned to him or her and to the promotion and forwarding of the business affairs of the Company and not to divert any business opportunities from the Company to himself or herself or to any other person or
business entity. 
 5.2 Conflicting Activities. The Employee will not, during the term of this Agreement, be engaged in any other
business activity in which is in competition, directly or indirectly with Company without the prior written consent of the Board. 
 5.3
Confidentiality. Without the prior written consent of the Company, except to the extent required by an order of a court having competent jurisdiction or under a subpoena from an appropriate government agency, the Employee will not communicate
or disclose to any third person, or use for the benefit of himself or herself any third person, (a) trade secrets, referral sources, customer or supplier lists or information, marketing plans, sales plans, management organization information
(including data and other information relating to members of the Board 

  
 3 

 
and management), operating policies or manuals, business plans, processes and techniques, financial records, or other financial, commercial, or business information relating to the Company or its
investors or the purchase and sale of its securities or any of its subsidiaries, or (b) information designated as confidential or proprietary that the Company or its subsidiaries and affiliates, if any, may receive from its suppliers,
customers, referral services or others who do business with the Company or any of its subsidiaries (collectively, “Confidential Information”) to any third person unless such Confidential Information has been previously disclosed to the
public by the Company or is in the public domain (other than by reason of the Employee’s breach of this Paragraph 5.3). 
 5.4 The
Company Property. The Employee hereby agrees that all documents, reports, plans, proposals, marketing and sales plans, client lists, referral lists and sources, client files and materials made by Employee or by the Company and its subsidiaries
are the properties of such entity and will not be used by Employee in any way adverse to the Company’s interests. The Employee will not deliver, reproduce or in any way allow such documents or things to be delivered or used by any third party
without specific written direction or written consent of the Board of the Company as appropriate. The Employee hereby assigns to the Company any rights which he or she may have in any such trade secret or proprietary information. Further, except as
expressly provided herein, promptly following the Employee’s termination of employment, the Employee will return to the Company all property, documents or papers used or owned by the Company and all copies, abstracts or summaries thereof in the
Employee’s possession or under his or her control. 
 5.5 Nonsolicitation of Patients, Employees, Customers or Referral Sources.
Employee acknowledges and agrees that customers issue from referral sources and referral sources issue from customers. Employee further agrees that customers and referral sources are interdependent and are interchangeable in this Agreement. During
the Employment Period and the two-year period following any termination of the Employee’s employment, the Employee will not directly or indirectly (i) solicit business from any patients, employees, customers, consultants or sources of
customer referrals, or (ii) solicit, encourage or induce any employee of the Company, its consultants, or any of its subsidiaries or affiliates to terminate employment with such entity, and will not directly or indirectly, either individually
or as owner, agent, employee, consultant or otherwise, employ or offer employment to any person who is or was employed by the Company, a subsidiary or affiliate thereof unless such person will have ceased to be employed by such entity. 

5.6 Competition with the Company. The Employee agrees that during the term of the Employee’s Employment Period and for a six
(6) month period of time thereafter (“Noncompete Term”) Employee will not, directly or indirectly, for his or her own benefit or on behalf of others, compete, own, operate, join, control, participate in, or be an officer, director,
consultant, partner, employee or holder of more than five percent (5%) of the capital stock or other equity interest of any corporation or other entity which competes with the Company or any of its subsidiaries, branches or affiliates anywhere
in the United States that the Company conducts such business during the Employment Period or at the date of Employee’s termination from the 

  
 4 

 
Company (“Competitive Activity”). Competitive Activity includes, but is not limited to, home health, hospice, critical access hospitals, hospital service providers and home and
community based services. The Company may extend the Noncompete Term for a period of an additional six (6) months (“Extended Noncompete Term”) by payment of 50% of employee’s Base Salary during the Extended Noncompete Term. In
addition, the Extended Noncompete Term may be further extended by the mutual agreement of the Company and the Employee. 
 5.7 Injunctive
Relief and Other Remedies with Respect to Covenants. The Employee acknowledges and agrees that the covenants and obligations of the Employee with respect to nonsolicitation, confidentiality, the Company property, noncompetition, and conflicting
activities, relate to special, unique and extraordinary maters and that a violation of any of the terms of such covenants and obligations will cause the Company irreparable injury for which adequate remedies are not available at law. Therefore, the
Employee agrees that the Company will (a) be entitled to an injunction, restraining order or such other equitable relief (without the requirement to post a bond) restraining the Employee from committing any violation of the covenants and
obligations contained in this Article 5 and (b) have no further obligation to make any payments to the Employee hereunder following any material violation of the covenants and obligations contained in this Article 5. These remedies are
cumulative and are in addition to any other rights and remedies the Company may have at law or in equity. 
 ARTICLE VI 

TERMINATION 
 6.1 Basis
for Termination. The Employee’s “at will” employment hereunder may be canceled or terminated at any time by either or any of the parties for cause or without cause or for any reason or no reason at all. 

6.2 Incapacity. This Agreement will automatically terminate on the last day of the month in which the Employee dies or becomes
permanently incapacitated. “Permanent incapacity” as used herein will mean mental or physical incapacity, or both, reasonably determined by the Board based upon a certification of such incapacity by, in the discretion of such Board, either
the Employee’s regularly attending physician or a duly licensed physician selected by the Board, rendering the Employee unable to perform substantially all of his or her duties hereunder and which appear reasonably certain to continue for at
least six consecutive months without substantial improvement. The Employee will be deemed to have “become permanently incapacitated” on the date the Board has determined that the Employee is permanently incapacitated and so notifies the
Employee. Upon termination of this Agreement pursuant to this Paragraph 6.2, the Company will grant pay to the Employee or the Employee’s estate within fourteen (14) days after termination an amount equal to the sum of (a) the
Employee’s Base Salary accrued to the date of termination; (b) any unreimbursed expenses accruing to the date of the termination of this Agreement; (c) any accrued, but unpaid vacation time; and (d) any earned but unpaid bonuses.
After any such termination, the Company will not be obligated to compensate the Employee, his or her estate or representatives except for the foregoing compensation then due and owing, nor provide the benefits to the Employee described in Article 3
(except as may be required by law). 

  
 5 

 6.3 With Cause. The Employee’s employment may be terminated by the Company “with
cause,” if any of the following occur: 
 (a) any material breach of the Employee’s obligations to the Company pursuant to this
Agreement; or 
 (b) any material acts or events which inhibit the Employee from fully performing his or her responsibilities to the Company
in good faith, including, but not limited to (i) a felony criminal conviction; (ii) any other criminal conviction involving the Employee’s lack of honesty or the Employee’s moral turpitude; (iii) drug or alcohol abuse; or
(iv) material acts of insubordination, dishonesty, gross carelessness or gross misconduct. 
 6.4 With Cause; Effective Date; Right
to be Heard. The Employee shall not be deemed to have been terminated for cause unless and until there shall have been delivered to him or her by the Board a notice of termination and a written statement of the reasons for Employee’s
termination for cause and Employee has had an opportunity to appear before the Board to state any protest that Employee may have concerning his or her termination for cause. If the Employee does not request an appearance before the Board pursuant to
this Paragraph 6.4 within five days from the date of receipt of the notice of termination and written statement of the reasons for his or her termination, the right to appear before the Board to protest shall be deemed to be waived and the
Employee’s termination shall be effective as of the date the notice of termination is delivered to Employee. If Employee elects to appear before the Board to protest his or her termination for cause, a specially called meeting will be called as
soon as practicable. At the specially called Board meeting, the Employee will have the opportunity to state any protest that he or she might have, orally (not to exceed one hour) or in writing, to his or her termination and the Board will thereafter
re-consider its decision to terminate the Employee for cause. If the Board decides to affirm its decision to terminate the Employee for cause, after the Employee’s appearance and protest before it, the Board’s decision: (i) will not
require a written statement of the reasons for the Board’s decision; (ii) will thereafter be final and non-appealable and (iii) effective as of the date of the Board’s final decision. The Employee will be suspended from his or
her responsibilities with pay, between the date that his or her original notice of termination is delivered and the Board’s final decision as to his or her termination for cause, if the Employee elects to protest his or her termination to the
Board, as set forth above. 
 6.5 Without Cause. The Employee’s employment may be terminated by the Company “without
cause” (for any reason or no reason at all) at any time by giving the Employee thirty (30) days’ prior written notice of termination. Termination of employment will occur at the conclusion of the notice period, unless otherwise agreed
to in writing by the Company and the Employee. 

  
 6 

 6.6 Termination by the Employee. The Employee may terminate his or her employment
hereunder by giving the Company thirty (30) days’ prior written notice. Termination of employment will occur at the conclusion of the notice period, unless otherwise agreed to in writing by the Company and the Employee. 

6.7 Payment Upon Termination With Cause by the Company or Volitional Termination by the Employee. Upon termination of the
Employee’s employment by the Company for cause pursuant to Paragraph 6.3 or volitional termination by the Employee pursuant to Paragraph 6.6, the Company will grant pay to the Employee within fourteen (14) days after termination an amount
equal to the sum of (a) the Employee’s Base Salary accrued to the date of termination; (b) any unreimbursed expenses, including accrued but unused vacation, accruing to the date of termination and (c) any earned but unpaid
bonuses. After any such termination, the Company will not be obligated to compensate the Employee, his or her estate or representatives except for the foregoing compensation then due and owing, nor provide the benefits to the Employee described in
Article 3 (except as may be required by law). 
 6.8 Payment Upon Termination Without Cause by the Company. Upon termination of the
Employee’s employment by the Company without cause pursuant to Paragraph 6.5, the Company will grant pay to the Employee within fourteen (14) days after termination an amount equal to the sum of (a) the Employee’s Base Salary
accrued to the date of termination; (b) the Employee’s Base Salary for the fifteen day notice period; (c) any unreimbursed expenses, including accrued but unused vacation, accruing to the date of termination; and (d) any earned
but unpaid bonuses. The Company will also continue to provide health benefits as covered in section 3.1(a) in this Agreement for a period of six (6) months or until such time as the Employee becomes eligible to participate in a similar health
plan. Should such termination without cause occur within the first 12 months of employment, a severance payment equivalent to 50% of Employee’s Base Salary will be due to Employee within fifteen (15) days after Employee’s final day of
employment. The Employee shall have no further rights to any additional monies for any reason excluding payments and benefits reference in section 6.8(a) through 6.8(d). Employee waives all right to receive any additional monies and claims (except
for workers compensation claims) and any such remedies are limited to the remedies set forth in this section. 
 ARTICLE VII 

MISCELLANEOUS 
 7.1
Survival. Articles 5 and 6 and Paragraphs 7.2, 7.3 and 7.15 will survive the termination hereof. 
 7.2 Indemnification. The
Company shall indemnify and hold harmless the Employee, to the maximum extent permitted by applicable law, against all costs, charges, and expenses incurred or sustained by the Employee in connection with any action, suit or proceeding to which he
may be made a party by reason of being an officer, director or employee of the Company or of any subsidiary or affiliate of the Company or any other corporation for which the Employee serves in good faith as an officer, director or employee at the
Company’s request. 

  
 7 

 7.3 Legal Fees and Expenses. Each party to pay their own attorney fees and costs. 

7.4 Binding Effect. This Agreement will be binding on, and will inure to the benefit of, the Company and any person or entity that
succeeds to the interest of the Company (regardless of whether such succession does or does not occur by operation of law) by reason of the sale of all or a portion of the Company’s stock, a merger, consolidation or reorganization involving the
Company or, unless the Company otherwise elects in writing, a sale of the assets of the business of the Company (or portion thereof) in which the Employee performs a majority of his or her services. This Agreement will also inure to the benefit of
the Employee’s heirs, executors, administrators and legal representatives. 
 7.5 Assignment. Except as provided under Paragraph
7.4, neither this Agreement nor any of the rights or obligations hereunder will be assigned or delegated by any party hereto without the prior written consent of the other party. 

7.6 Entire Agreement. This Agreement constitutes the entire understanding between the parties hereto with respect to the matters
referred to herein. No other agreement relating to the terms of the Employee’s employment by the Company, oral or otherwise, will be binding between the parties unless it is in writing and signed by the party against whom enforcement is sought.
There are no promises, representations, inducements or statements between the parties other than those that are expressly contained herein. The Employee acknowledges that he or she is entering into this Agreement o his or her own free will and
accord, and with no duress, that he or she has read this Agreement and that he or she understands the Agreement and its legal consequences. 

7.7 Severability; Reformation. In the event that one or more of the provisions of this Agreement become invalid, illegal or
unenforceable in any respect, the validity, legality and enforceability of the remaining provisions contained herein will not be affected thereby. In the event that any of the provisions of Paragraphs 5.4, 5.5, 5.6 or 5.7 are not enforceable in
accordance with its terms, the Employee and the Company agree that such Paragraph will be reformed to make such Paragraph enforceable in a manner which provides the Company the maximum rights permitted at law, including but not limited to the
duration, geographic area and subject matter covered by these provisions. Further, it is the intent of the parties that this Agreement be complaint with all state and federal laws regarding compensation in and among medical businesses, including
anti-kickback provisions. To the extent that any of the provisions herein are in violation of those provisions, such violation is unintentional and the Agreement may be reformed to make the provisions compliant. 

7.8 Waivers. Waiver by any party hereto of any breach or default by the other party of any of the terms of this Agreement will not
operate as a waiver of any other breach or default, whether similar to or different from the breach or default waived. No waiver of any provision of this Agreement will be implied from any course of dealing between the parties hereto or from any
failure by either party hereto to assert its or his or her rights hereunder on any occasion or series of occasions. 

  
 8 

 7.9 Notices. Any notice required or desired to be delivered under this Agreement will be
in writing and will be delivered personally, by courier service, by registered mail, return receipt requested, or by facsimile and will be effective upon actual receipt by the party to which such notice will be directed, and will be addressed as
follows (or to such other address as the party entitled to notice will hereafter designate in accordance with the terms hereof): 
 If to
the Company: 
 First Physicians Capital Group, Inc. 

9663 Santa Monica Blvd., #959 

Beverly Hills, CA 90210 
 with a
copy to: 
 Christensen Law Group, P.L.L.C. 

Attention: J. Clay Christensen 

700 Oklahoma Tower 
 210 Park
Avenue 
 Oklahoma City, Oklahoma 73102 

If to the Employee: 
 The home
address of the Employee noted on the records of the Company. 
 7.10 Amendments. This Agreement may not be altered, modified or
amended except by a written instrument signed by each of the parties hereto. 
 7.11 Headings. Headings to paragraphs in this
Agreement are for the convenience of the parties only and are not intended to be part of or to affect the meaning or interpretation hereof. 

7.12 Counterparts. This Agreement may be executed in counterparts, each of which will be deemed an original but all of which together
will constitute one and the same instrument. 
 7.13 Withholding. Any payments provided for herein will be reduced by any amounts
required to be withheld by the Company from time to time under applicable federal, state or local income or employment tax laws or similar statutes or other provisions of law then in effect. 

7.14 Governing Law. This Agreement will be governed by and construed in accordance with the laws of the State of Delaware, without
reference to principles of conflicts or choice of law under which the law of any other jurisdiction would apply. This Agreement will not be construed for or against a party because that party prepared it. 

  
 9 

 7.15 Consent to Jurisdiction. Each of the parties hereto hereby irrevocably and
unconditionally submits, for itself and its property, to the exclusive jurisdiction of any Delaware state court, or, if no such state court has proper jurisdiction, the Federal court of the United States of America, sitting in Delaware, and any
appellate court from any thereof, in any proceedings arising out of or relating to this Agreement and any transactions contemplated hereby or for recognition or enforcement of any judgment relating thereto, and each of the parties hereby irrevocably
and unconditionally (i) agrees not to commence any such proceeding except in such courts, (ii) agrees that any claim in respect of any such proceeding may be heard and determined in such Delaware state court or, if no such state court has
proper jurisdiction, the such Federal court, (iii) waives, to the fullest extent it may legally and effectively do so, any objection which it may now or hereafter have to the laying of venue of any Proceeding in the state or Federal courts
located in any such Delaware state or Federal court, and (iv) waives, to the fullest extent permitted by law, the defense of an inconvenient forum to the maintenance of such proceeding in the state or Federal courts located in any such Delaware
state or Federal court. Each of the parties hereto agrees that a final judgment in any such proceeding shall be conclusive and may be enforced in other jurisdictions in the United States and throughout the world by suit on the judgment or in any
other manner provided by law. 
 7.16 Right of Set-Off. Upon termination or expiration of this Agreement, the Company will have the
right to set-off against the amounts due the Employee hereunder the amount of any outstanding loan or advance from the Company to the Employee. 
 THE
PARTIES TO THIS AGREEMENT HEREBY ACKNOWLEDGE THAT THEY HAVE READ AND UNDERSTAND THE AGREEMENT AND CONSENT AND AGREE TO BE BOUND BY ALL OF THE TERMS AND CONDITIONS THEREOF. 

IN WITNESS WHEREOF, the Corporation has caused this Agreement to be executed by its duly authorized officer and the Employee has hereunto set his or
her hand as of the day and year first above written. 
  

	
	THE EMPLOYEE:
	
	 /s/ Sean Kirrane

  
 10 

 
			
	THE COMPANY:
	
	FIRST PHYSICIANS CAPITAL GROUP, INC.
		
	By:	 	 /s/ Richardson Sells

	Name:	 	Richardson Sells
	Title:	 	Chair of the Compensation Committee

  
 11

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00231-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00231-of-00352.parquet"}]]